AlphAIAlphAI — Financial news for AI agents
globenewswire.comOCT 52 min read$NMTC

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NeuroOne reported preliminary Q4 2026 product revenue of $3.8M, up 38.4% YoY, and full-year revenue of $10.5M, up 15.6%. The company secured a record $4.5M purchase order, with $1M shipped in September and the rest expected in Q1-Q2 2027. Total open orders reached $5.4M by September 30, 2026.

Original reporting
globenewswire.com
Published Oct 5, 2026, 1:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 1:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$NMTC
Bullish
high confidence
Mentioned
$NMTC
Relevance
6/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$NMTCBullishMed
01

Why it matters

The preliminary figures provide the first public glimpse of the company's 2026 performance, setting expectations ahead of the formal 10‑K filing.

02

Market read

First‑time disclosure of strong revenue growth and a record order could move NMTC's stock ahead of its December earnings filing.

03

What to watch

Potential reimbursement or regulatory hurdles for the new trigeminal neuralgia system.

Relevance 6/10Novelty 7/10Timing: today

Background

NeuroOne is a Nasdaq‑listed medical‑technology firm focused on neurological disorder treatment devices.

Company-level read

Ticker impact

$NMTCBullishHigh confidence
Context

NeuroOne disclosed preliminary Q4 2026 product revenue of $3.8M, a 38.4% YoY increase, and a record $4.5M purchase order.

Expected impact

likely upward pressure as investors price in higher revenue and cash flow visibility.

Evidence & confidence

The disclosed growth rates and record order are fresh, material information for a micro‑cap medical‑tech stock.

Market effects

Sector

May boost sentiment for niche neuro‑technology and minimally invasive surgical device sector.

Regional

Limited to U.S. small‑cap biotech/medical‑tech investors.

Global

Minimal; primarily affects NeuroOne and its immediate peers.

Counterpoint

What could challenge this read

If the order faces manufacturing delays, the revenue boost could be overstated.

Key entities

  • company
    NeuroOne Medical Technologies Corporation

    Issuer of the disclosed revenue and purchase order.

  • executive
    Dave Rosa

    CEO who commented on the company's momentum.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 5
$NMTCLow

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range

SEC EDGAR 8-K1 min
AUG 27
$NMTCMed

EQS-News: NeuroOne Medical Technologies: NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED Platform

NeuroOne Medical Technologies (NMTC) reported successful large-animal procedures using its StereoCED platform for drug delivery and electrophysiological monitoring. The company expects to launch human clinical studies this quarter and recognize related revenue in fiscal Q4 2026. The procedures were conducted at the University of Minnesota, demonstrating technical feasibility and validating the integrated surgical and drug delivery workflow.

finanznachrichten.de2 min
AUG 15
Med

NeuroOne Medical Technologies Corporation Q3 2026 Earnings Call Summary

NeuroOne Medical Technologies reported Q3 2026 revenue up 16%, driven by demand for its OneRF Brain Ablation System, though recognized revenue was limited by manufacturing lead times. Gross margin rose to 59.9%. Management cited ISO 13485 certification, guidance of $9.2M to $10.5M for FY2026, and a second manufacturing site expected in early 2027.

yahoo.com6 min
AUG 13
$NMTCMed

EQS-News: NeuroOne Medical Technologies: NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NeuroOne Medical Technologies (Nasdaq: NMTC) reported fiscal Q3 2026 results for the quarter ended June 30, 2026. Product revenue rose 16% YoY to $2.0M and product gross margins expanded to 59.9%. New product orders were $2.7M, lifting backlog to $1.7M, and FY2026 orders totaled $11.2M. The company also cited ISO 13485 certification and updates on StereoCED and OneRF platforms.

finanznachrichten.de7 min
AUG 13
$NMTCMed

NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% $2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product Orders for Fiscal Year 2026 of $11.2 Million; Wo

SEC EDGAR 8-K6 min
OCT 22
$ASBHighAI 8/10

Associated Banc-Corp Q3 2026 slides: margin hits decade high

Associated Banc-Corp (ASB) reported Q3 2026 earnings, beating estimates with adjusted EPS of $0.81. Net interest margin expanded to 3.20%, a decade high. Loans and deposits grew, with strategic shifts toward higher-yielding commercial relationships. Shares rose 2.16% to $29.81. Management maintained guidance for continued margin expansion.

investing.com3 min